CYCN - Cyclerion Therapeutics

-

$undefined

N/A

(N/A)

Cyclerion Therapeutics NasdaqCM:CYCN Cyclerion Therapeutics, Inc., a biopharmaceutical company, develops treatments for serious diseases serious diseases with novel sGC stimulators in both the central nervous system (CNS) and the periphery. It is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to treat cardiovascular diseases; and Praliciguat, a systemic sGC stimulator for the treatment of rare kidney disease. It has a license agreement with Akebia to develop, manufacture, medical affair, and commercializes Praliciguat and other related products. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

Location: 245 First Street, Riverview II, Cambridge, MA, 02142, United States | Website: https://www.cyclerion.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

5.253M

Cash

3.639M

Avg Qtr Burn

-857.5K

Short % of Float

1.09%

Insider Ownership

32.73%

Institutional Own.

12.22%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Zagociguat (CY6463) Details
Neurological disorder, Alzheimer's disease, Dementia

Phase 2

Update

Zagociguat (CY6463) Details
Cognitive Impairment Associated with Schizophrenia

Phase 1b

Update

Zagociguat (CY6463) Details
Rare diseases, Mitochondrial disease, Rare genetic disease

Failed

Discontinued

Failed

Discontinued

Olinciguat Details
Sickle cell disease

Failed

Discontinued